On December 1, 2011, the Federal Circuit declined to overturn a lower court ruling that Finnegan client AstraZeneca PLC did not infringe a Teva patent through its sales of the billion-dollar cholesterol drug Crestor®. The court held that Teva’s patent for a stabilized statin formulation of rosuvastatin calcium for the treatment of dyslipidemia was invalid since AstraZeneca was first to invent the pharmaceutical compound.
